CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, today announces the launch of ioAstrocytes. This new addition to bit.bio’s ioCells portfolio creates an unparalleled toolkit for disease research that addresses the challenges of data reproducibility and enables accelerated therapeutic development..

英国剑桥--（商业新闻短讯）--bit.bio，一家为人类细胞编码新疗法的公司，也是合成生物学领域的先驱，今天宣布推出ioAstrocytes。bio的ioCells产品组合为疾病研究创造了一个无与伦比的工具包，可以解决数据可重复性的挑战，并加速治疗发展。。

ioCells, iPSC-derived cells for research and drug discovery, are manufactured using bit.bio's deterministic programming technology, opti-ox, and are considered best in class for their functionality, consistency, and scalability. With 18 launches to date in 2024, bit.bio’s ioCells portfolio comprises 37 products, including ioWild Type Cells, ioDisease Model Cells and ioCRISPR-Ready Cells..

ioCells是用于研究和药物发现的iPSC衍生细胞，使用bit.bio的确定性编程技术opti-ox制造，因其功能性，一致性和可扩展性而被认为是同类中最好的。bit.bio的ioCells产品组合包括37种产品，包括野生型细胞、碘化酶模型细胞和ioCRISPR就绪细胞，截至2024年共推出18种。。

Astrocytes are a type of glial cell in the brain involved in a wide range of processes, including neural signalling, homeostasis maintenance, and immune response regulation. The significance of astrocytes for effectively modelling the human brain is frequently underestimated. Growing evidence highlights the important role of astrocytes in CNS conditions, such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy, pain disorders, and neuropsychiatric conditions.

。星形胶质细胞对有效模拟人脑的重要性经常被低估。越来越多的证据强调了星形胶质细胞在中枢神经系统疾病中的重要作用，如多发性硬化症，阿尔茨海默病，帕金森病，癫痫，疼痛障碍和神经精神疾病。

With the introduction of ioAstrocytes, scientists now have access to defined, consistent, and functional human astrocytes optimised for co-culture with other CNS cell types..

随着星形胶质细胞的引入，科学家现在可以获得定义的，一致的和功能性的人类星形胶质细胞，这些星形胶质细胞可以与其他中枢神经系统细胞类型共培养。。

'We are excited to expand the universe of ioCells with ioAstrocytes and offer researchers worldwide access to the major cell types of the human brain,” said Mark Kotter, Founder and CEO of bit.bio. 'Much like building blocks, scientists can combine different CNS cell types with or without disease-specific mutations to explore their interactions.

bit.bio创始人兼首席执行官马克·科特（Mark Kotter）说：“我们很高兴能用星形胶质细胞扩大ioCells的范围，并为全球研究人员提供人类大脑主要细胞类型的途径。就像构建模块一样，科学家可以将不同的中枢神经系统细胞类型与疾病特异性突变结合起来，探索它们之间的相互作用。

We look forward to seeing how the neuroscience community will leverage this powerful toolkit to further our understanding of the CNS and develop much needed therapies for neurological conditions.”.

我们期待着看到神经科学界如何利用这个强大的工具包来加深我们对中枢神经系统的理解，并开发出急需的神经疾病治疗方法。”。

ioAstrocytes are highly defined, consistent, and functional human astrocytes, optimised for co-culture with other CNS cell types. They display stellate morphology, express key markers, and perform essential astrocyte functions such as phagocytosis, secretion of cytokines, and modulation of neuronal activity when co-cultured with CNS cells..

星形胶质细胞是高度定义的，一致的和功能性的人类星形胶质细胞，优化用于与其他CNS细胞类型的共培养。当与中枢神经系统细胞共培养时，它们显示星状形态，表达关键标志物，并执行基本的星形胶质细胞功能，例如吞噬作用，细胞因子分泌和神经元活性调节。。

“ioAstrocytes represent a significant addition to bit.bio's growing ioCells portfolio, enabling researchers to enhance in-vitro CNS models and accelerate discoveries,” said Farah Patell-Socha, Vice President of Research Products at bit.bio. 'By providing highly consistent cells with essential functional properties of human astrocytes, we’re unlocking novel ways for advancing neuroinflammation research, conducting in-depth neural network studies, and performing screening and toxicity assessments for potential therapeutics.'.

bit.bio研究产品副总裁法拉·帕特尔·索查（FarahPatell Socha）说：“ioAstrocytes是bit.bio不断增长的ioCells组合的重要补充，使研究人员能够增强体外中枢神经系统模型并加速发现。通过提供具有人类星形胶质细胞基本功能特性的高度一致的细胞，我们正在为推进神经炎症研究、进行深入的神经网络研究以及对潜在疗法进行筛选和毒性评估开辟新的途径。”。

For more information or to purchase bit.bio’s ioAstrocytes, please visit the Product page.

欲了解更多信息或购买bit.bio的星形胶质细胞，请访问产品页面。

About bit.bio

关于bit.bio

bit.bio, a synthetic biology company, is democratising human cells to advance biomedical research (SDG9) and enable transformative treatments (SDG3). With Nobel Prize-winning science underpinning our understanding of cell identity as defined by unique combinations of transcription factors, our deterministic cell programming technology, opti-ox, enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step.

。随着诺贝尔奖获得者的科学支持我们对转录因子独特组合所定义的细胞身份的理解，我们的确定性细胞编程技术opti-ox能够在一步中将诱导多能干细胞（iPSC）转化为任何所需的人类细胞类型。

This is achieved within days and at industrial scale, while maintaining exceptional purity and consistency. We are creating highly differentiated human cell products for research and drug discovery (ioCells) and cell therapy (txCells). Our growing commercial ioCells portfolio comprises ioWild Type Cells, ioDisease Model Cells and ioCRISPR-Ready Cells.

这可以在几天内以工业规模实现，同时保持优异的纯度和一致性。我们正在为研究和药物发现（ioCells）和细胞治疗（txCells）创造高度分化的人类细胞产品。我们不断增长的商业ioCells组合包括ioWild型细胞，碘化酶模型细胞和ioCRISPR就绪细胞。

Our cell therapy pipeline is currently focused on metabolism and endocrinology, immunology and neurology therapeutic areas. Our lead candidate, bbHEP01 (encapsulated allogeneic txHepatocytes), is in development for acute liver diseases. Additionally, we are collaborating with BlueRock Therapeutics (a wholly owned independently operated subsidiary of Bayer AG) on regulatory T cell (Treg)-based cell therapies..

我们的细胞治疗渠道目前专注于代谢和内分泌学，免疫学和神经病学治疗领域。我们的主要候选者bbHEP01（包封的同种异体txHepatocytes）正在开发用于急性肝病。此外，我们正在与BlueRock Therapeutics（拜耳公司的全资独立运营子公司）合作，开发基于调节性T细胞（Treg）的细胞疗法。。

Since spinning out from the University of Cambridge and launching in 2016, we have raised approximately $200m from leading investors, including Arch Venture, Blueyard Capital, Charles River Laboratories, Foresite Capital, Milky Way, National Resilience, and Tencent.

自2016年从剑桥大学（University of Cambridge）推出以来，我们已经从主要投资者那里筹集了约2亿美元，包括Arch Venture、Blueyard Capital、Charles River Laboratories、Foresite Capital、银河、National Resility和腾讯。